Literature DB >> 19701890

A role for HVEM, but not lymphotoxin-beta receptor, in LIGHT-induced tumor cell death and chemokine production.

Christine Pasero1, Bernadette Barbarat, Sylvaine Just-Landi, Alain Bernard, Thérèse Aurran-Schleinitz, Jérome Rey, Eric Eldering, Alemsedeg Truneh, Régis T Costello, Daniel Olive.   

Abstract

The TNF member LIGHT also known as TL4 or TNFSF14) can play a major role in cancer control via its two receptors; it induces tumor cell death through lymphotoxin-beta receptor (LT-betaR) and ligation to the herpes virus entry mediator (HVEM) amplifies the immune response. By studying the effect of LIGHT in the transcriptional profile of a lymphoid malignancy, we found that HVEM, but not LT-betaR, stimulation induces a significant increase in the expression of chemokine genes such as IL-8, and an unexpected upregulation of apoptotic genes. This had functional consequences, since LIGHT, or HVEM mAb, thus far known to costimulate T- and B-cell activation, induced chronic lymphocytic leukemia cell death. Many of the mediators involved were identified here, with an apoptotic pathway as demonstrated by caspases activation, decrease in mitochondrial membrane potential, upregulation of the pro-apoptotic protein Bax, but also a role of TRAIL. Moreover, HVEM induced endogenous TNF-alpha production and TNF-alpha enhanced HVEM-mediated cell death. HVEM function was mainly dependent on LIGHT, since other ligands like HSV-glycoprotein D and B and T lymphocyte attenuator were essentially ineffective. In conclusion, we describe a novel, as yet unknown killing effect of LIGHT through HVEM on a lymphoid malignancy, and combined with induction of chemokine release this may represent an additional tool to boost cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19701890     DOI: 10.1002/eji.200939069

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

1.  BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction.

Authors:  Nicholas J Shubin; Chun S Chung; Daithi S Heffernan; Lydea R Irwin; Sean F Monaghan; Alfred Ayala
Journal:  J Leukoc Biol       Date:  2012-03-29       Impact factor: 4.962

2.  Herpesvirus entry mediator (HVEM) attenuates signals mediated by the lymphotoxin β receptor (LTβR) in human cells stimulated by the shared ligand LIGHT.

Authors:  John Bechill; William J Muller
Journal:  Mol Immunol       Date:  2014-06-28       Impact factor: 4.407

3.  Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory.

Authors:  Jang-June Park; Sudarshan Anand; Yuming Zhao; Yumiko Matsumura; Yukimi Sakoda; Atsuo Kuramasu; Scott E Strome; Lieping Chen; Koji Tamada
Journal:  Cancer Immunol Immunother       Date:  2011-08-30       Impact factor: 6.968

4.  Excess LIGHT contributes to placental impairment, increased secretion of vasoactive factors, hypertension, and proteinuria in preeclampsia.

Authors:  Wei Wang; Nicholas F Parchim; Takayuki Iriyama; Renna Luo; Cheng Zhao; Chen Liu; Roxanna A Irani; Weiru Zhang; Chen Ning; Yujin Zhang; Sean C Blackwell; Lieping Chen; Lijian Tao; M John Hicks; Rodney E Kellems; Yang Xia
Journal:  Hypertension       Date:  2013-12-09       Impact factor: 10.190

Review 5.  Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases.

Authors:  A Sabokbar; D J Mahoney; F Hemingway; N A Athanasou
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

Review 6.  Targeting costimulatory molecules to improve antitumor immunity.

Authors:  Daria Capece; Daniela Verzella; Mariafausta Fischietti; Francesca Zazzeroni; Edoardo Alesse
Journal:  J Biomed Biotechnol       Date:  2012-02-12

7.  Potential therapeutic effect of the secretome from human uterine cervical stem cells against both cancer and stromal cells compared with adipose tissue stem cells.

Authors:  Noemí Eiró; Juan Sendon-Lago; Samuel Seoane; María A Bermúdez; Maria Luz Lamelas; Tomás Garcia-Caballero; José Schneider; Roman Perez-Fernandez; Francisco J Vizoso
Journal:  Oncotarget       Date:  2014-11-15

Review 8.  Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine.

Authors:  Francisco J Vizoso; Noemi Eiro; Sandra Cid; Jose Schneider; Roman Perez-Fernandez
Journal:  Int J Mol Sci       Date:  2017-08-25       Impact factor: 5.923

9.  Systemic Delivery of mLIGHT-Armed Myxoma Virus Is Therapeutic for Later-Stage Syngeneic Murine Lung Metastatic Osteosarcoma.

Authors:  John D Christie; Nicole Appel; Liqiang Zhang; Kenneth Lowe; Jacquelyn Kilbourne; Juliane Daggett-Vondras; Natalie Elliott; Alexandra R Lucas; Joseph N Blattman; Masmudur M Rahman; Grant McFadden
Journal:  Cancers (Basel)       Date:  2022-01-11       Impact factor: 6.639

10.  Oncolytic adenovirus encoding LIGHT (TNFSF14) inhibits tumor growth via activating anti-tumor immune responses in 4T1 mouse mammary tumor model in immune competent syngeneic mice.

Authors:  Shiyun Dai; Yun Lv; Weidong Xu; Yuefeng Yang; Chao Liu; Xiwen Dong; Huan Zhang; Bellur S Prabhakar; Ajay V Maker; Prem Seth; Hua Wang
Journal:  Cancer Gene Ther       Date:  2020-04-20       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.